Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
0.7556
-0.0207 (-2.67%)
Apr 29, 2025, 4:00 PM EDT - Market closed

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.

The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease.

It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.

Palisade Bio, Inc.
Palisade Bio logo
Country United States
Founded 1996
Industry Biotechnology
Sector Healthcare
Employees 8
CEO J. Finley

Contact Details

Address:
7750 El Camino Real, Suite 2A
Carlsbad, California 92009
United States
Phone 858 704 4900
Website palisadebio.com

Stock Details

Ticker Symbol PALI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001357459
CUSIP Number 696389105
ISIN Number US6963892046
Employer ID 52-2007292
SIC Code 2836

Key Executives

Name Position
J. D. Finley Chief Executive Officer, Chief Financial Officer and Director
Dr. Mitchell Lawrence Jones M.D., Ph.D. Chief Operating Officer and Chief Medical Officer
Dr. Joerg Heyer Ph.D. Head of Translational Science and Medicine
Ryker Willie Senior Vice President of Finance and Corporate Controller

Latest SEC Filings

Date Type Title
Mar 24, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Dec 17, 2024 424B3 Prospectus
Dec 17, 2024 424B3 Prospectus
Dec 17, 2024 424B3 Prospectus
Dec 16, 2024 EFFECT Notice of Effectiveness
Dec 16, 2024 8-K Current Report
Dec 13, 2024 424B5 Filing
Dec 13, 2024 POS AM Post-Effective amendments for registration statement
Dec 12, 2024 EFFECT Notice of Effectiveness